Centene stock in selloff after rare earnings miss (CNC:NYSE)

Centene (CNC) shares dropped approximately 10% in premarket trading after the company reported its first earnings miss in four years for Q2 2025, swinging to a loss of $0.16 per share. This performance was driven by rising medical costs, particularly in its ACA Marketplace and Medicaid businesses, which pushed its Health Benefits Ratio to 93.0%. Consequently, Centene significantly cut its 2025 EPS guidance to $1.75 from a $2.94 consensus, citing a $2.4 billion impact from these adverse cost trends, a development that also saw peers like Molina and Elevance Health decline.

Analysis

Centene (CNC) reported a significant deterioration in its financial performance for Q2 2025, marking its first earnings miss in four years and causing a sharp negative reaction in its stock. The company swung to an adjusted loss per share of $0.16, a stark contrast to the $2.42 earnings per share in the prior-year period. This was driven by a severe spike in its health benefits ratio (HBR) to 93.0%, substantially higher than the 87.6% recorded a year ago and the 91.6% consensus estimate, indicating a critical failure to manage rising medical costs. The company pinpointed these adverse trends to its ACA Marketplace and Medicaid businesses, which are central to its operating model. While revenues of $48.7B surpassed consensus by a notable $4.5B, this top-line strength was completely negated by the collapse in profitability. The most damaging development is the drastic reduction in full-year 2025 EPS guidance to $1.75, far below the $2.94 consensus, which institutionalizes the negative outlook by pricing in a $2.4B hit from these cost trends. The negative sentiment cascaded to peers including Molina Healthcare (MOH) and Elevance Health (ELV), suggesting investor concern about systemic cost pressures across the managed care sector.

Key Decisions for Investors

• Given the severe cut in 2025 EPS guidance to $1.75, investors should treat the previous earnings trajectory as broken and re-evaluate any long thesis on Centene until management demonstrates tangible control over medical cost trends.
• The contagion effect on peers suggests a sector-wide risk; investors should increase scrutiny on the Health Benefits Ratio (HBR) for all managed care holdings, particularly those with high exposure to the ACA Marketplace.
• The significant disconnect between Centene's strong revenue growth and its collapsing profitability makes future HBR figures the single most important metric to monitor for any potential recovery.